Diagnostic Potential of Serum Proteomic Patterns in Prostate Cancer

Bañez, Lionel L.; Prasanna, Premakala; Sun, Leon; Ali, Amina; Zou, Zhiqiang; Adam, Bao Ling; McLeod, David G.; Moul, Judd W.; Srivastava, Shiv

doi:10.1097/01.ju.0000069431.95404.56

Cited by 118 publications

(60 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, specific serum protein patterns have recently been detected in patients with different grades of astrocytomas (Liu et al, 2005). Similar results have also been obtained in studies of carcinoma in prostate (Adam et al, 2002;Banez et al, 2003), breast (Vlahou et al, 2003) and ovaria (Petricoin et al, 2002).…”

supporting

confidence: 68%

Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment

et al. 2006

View full text Add to dashboard Cite

Radiotherapy is one of the mainstays of glioblastoma (GBM) treatment. This study aims to investigate and characterise differences in protein expression patterns in brain tumour tissue following radiotherapy, in order to gain a more detailed understanding of the biological effects. Rat BT4C glioma cells were implanted into the brain of two groups of 12 BDIX-rats. One group received radiotherapy (12 Gy single fraction). Protein expression in normal and tumour brain tissue, collected at four different time points after irradiation, were analysed using surface enhanced laser desorption/ionisation -time of flight -mass spectrometry (SELDI-TOF-MS). Mass spectrometric data were analysed by principal component analysis (PCA) and partial least squares (PLS). Using these multivariate projection methods we detected differences between tumours and normal tissue, radiation treatment-induced changes and temporal effects. 77 peaks whose intensity significantly changed after radiotherapy were discovered. The prompt changes in the protein expression following irradiation might help elucidate biological events induced by radiation. The combination of SELDI-TOF-MS with PCA and PLS seems to be well suited for studying these changes. In a further perspective these findings may prove to be useful in the development of new GBM treatment approaches.

show abstract

supporting

confidence: 68%

Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Use of protein markers and marker fragments in combination is likely to confer higher specificity than using any single one. [12][13][14][15] Singular value decomposition (SVD) was applied to the data of the 2 forms of ApoA1 and 4 forms of transthyretin to allow for visualization at reduced dimension. 16 The groups of ovarian cancer samples, controls and the breast, colon and prostate cancer samples each formed overlapping but distinguishable clusters with moderately good separation from one another in the 2-dimensional space spanned by the first and third components of the SVD analysis (Fig.…”

Section: Resultsmentioning

confidence: 99%

Classification of cancer types by measuring variants of host response proteins using SELDI serum assays

Fung¹,

Yip²,

Lomas³

et al. 2005

Intl Journal of Cancer

168

160

View full text Add to dashboard Cite

Protein expression profiling has been increasingly used to discover and characterize biomarkers that can be used for diagnostic, prognostic or therapeutic purposes. Most proteomic studies published to date have identified relatively abundant host response proteins as candidate biomarkers, which are often dismissed because of an apparent lack of specificity. We demonstrate that 2 host response proteins previously identified as candidate markers for early stage ovarian cancer, transthyretin and inter-alpha trypsin inhibitor heavy chain 4 (ITIH4), are posttranslationally modified. These modifications include proteolytic truncation, cysteinylation and glutathionylation. Assays using Surface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry (SELDI-TOF-MS) may provide a means to confer specificity to these proteins because of their ability to detect and quantitate multiple posttranslationally modified forms of these proteins in a single assay. Quantitative measurements of these modifications using chromatographic and antibody-based ProteinChip1 array assays reveal that these posttranslational modifications occur to different extents in different cancers and that multivariate analysis permits the derivation of algorithms to improve the classification of these cancers. We have termed this process host response protein amplification cascade (HRPAC), since the process of synthesis, posttranslational modification and metabolism of host response proteins amplifies the signal of potentially low-abundant biologically active disease markers such as enzymes. ' 2005 Wiley-Liss, Inc.

show abstract

“…Possibly, the other discriminative m/z's at 4289 and 8151 that we found with this procedure have more potential as biomarkers for RCC. A decrease of a peak at 4289 Da has been mentioned for several other cancers, 32,33 one group attributing this mass to a fragment of inter-a trypsin inhibitor heavy chain 4. 33 Also, peaks with an m/z similar to 8151 have been reported as biomarker candidates.…”

Section: Discussionmentioning

confidence: 99%

Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations

Engwegen

Mehra

Haanen

et al. 2007

Laboratory Investigation

View full text Add to dashboard Cite

Currently, no suitable biomarker for the early detection or follow-up of renal cell carcinoma (RCC) is available. We aimed to validate previously reported potential serum biomarkers for RCC obtained with Surface Enhanced Laser Desorption Ionisation-Time of Flight Mass Spectrometry (SELDI-TOF MS) in our laboratory using distinct patient populations. Two sets of sera from RCC patients and healthy controls (HC) were gathered from different institutes and analysed according to published procedures. The first set (40 RCC, 32 HC) consisted of mainly presurgery samples from patients with disease stages I-IV. The second set (26 RCC, 27 HC) were mostly sera from patients with stage-IV disease, drawn after nephrectomy. Only the increased expression of the previously found serum amyloid-a (SAA) peak cluster could be validated in a similar RCC patient subset in both our populations in two independent analyses. It was seen both in earlyand late-stage disease and in pre-and postsurgery samples. These results were also confirmed by ELISA. Other previously identified biomarker candidates (mass-to-charge ratio's (m/z) 3900, 4107, 4153, 5352 and 5987) proved difficult to reproduce upon duplicate analysis. Modification of the analytical protocol for these markers resulted in their detection, but we did not achieve satisfactory classification of patients and controls with these alleged biomarkers in any of our two sample sets. Instead, two new peaks (m/z 4289 and 8151) were identified with better performance (sensitivity and specificity B65-90%) for separating patients from controls in the first sample set. Concluding, only the SAA peak cluster was validated as a robust RCC biomarker candidate, which is present in a specific subset of these patients, regardless of disease stage or nephrectomy status. In addition, two new peaks were seen which might prove useful as biomarkers, provided these are validated in new populations. Renal cell carcinoma (RCC) is difficult to diagnose at early stages due to a lack of clear clinical symptoms. When symptoms do occur, about 30% of patients already have metastatic disease. In addition, a similar part of patients with resection of localised disease will have a recurrence. 1 Therefore, a need remains for reliable markers for diagnosis and follow-up of RCC, preferably in easy-accessible body fluids. Surface Enhanced Laser Desorption Ionisation-Time of Flight Mass Spectrometry (SELDI-TOF MS) 2,3 is being increasingly used to search for new and better tumour markers in (serum) protein profiles, for example, for ovarian, 4 breast, 5 prostate 6 and colorectal cancer. 7 Its appeal lies in the ease with which a multitude of samples can be analysed with a minimum of sample preparation in a single SELDI-TOF MS analysis. Indeed, SELDI-TOF MS has also been performed to identify biomarker proteins for early detection of RCC. Two studies describe protein profiling of serum with SELDI-TOF MS. 8,9 Tolson et al 8 reported a peak cluster at a mass-to-charge ratio (m/z) of approximately 11 000 from serum amyloid a-...

show abstract

Diagnostic Potential of Serum Proteomic Patterns in Prostate Cancer

Cited by 118 publications

References 15 publications

Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment

Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment

Classification of cancer types by measuring variants of host response proteins using SELDI serum assays

Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations

Contact Info

Product

Resources

About